Aethlon Medical, Inc. Logo

Aethlon Medical, Inc.

AEMD

(0.8)
Stock Price

0,58 USD

-100.73% ROA

-40064.1% ROE

-0.26x PER

Market Cap.

5.533.108,00 USD

9.98% DER

0% Yield

0% NPM

Aethlon Medical, Inc. Stock Analysis

Aethlon Medical, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Aethlon Medical, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (9%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-76.3%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-78.86%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 PBV

The stock's elevated P/BV ratio (3.02x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Aethlon Medical, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Aethlon Medical, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Aethlon Medical, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Aethlon Medical, Inc. Revenue
Year Revenue Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 1.359.621 100%
2013 1.230.004 -10.54%
2014 1.623.769 24.25%
2015 762.417 -112.98%
2016 886.572 14%
2017 392.073 -126.12%
2018 149.625 -162.04%
2019 229.625 34.84%
2020 650.187 64.68%
2021 659.104 1.35%
2022 294.165 -124.06%
2023 0 0%
2023 574.245 100%
2024 0 0%
2025 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Aethlon Medical, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 1.440.000 100%
2014 1.509.000 4.57%
2015 1.028.000 -46.79%
2016 782.000 -31.46%
2017 673.000 -16.2%
2018 586.000 -14.85%
2019 896.000 34.6%
2020 927.000 3.34%
2021 2.072.000 55.26%
2022 2.341.000 11.49%
2023 0 0%
2023 2.745.000 100%
2024 2.520.000 -8.93%
2025 1.658.632 -51.93%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Aethlon Medical, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1997 0
1998 0 0%
1999 0 0%
2000 857.727 100%
2001 1.866.262 54.04%
2002 2.068.728 9.79%
2003 1.637.081 -26.37%
2004 995.549 -64.44%
2005 2.183.377 54.4%
2006 2.013.217 -8.45%
2007 2.084.254 3.41%
2008 2.892.588 27.95%
2009 2.074.464 -39.44%
2010 2.848.892 27.18%
2011 4.557.116 37.48%
2012 4.473.956 -1.86%
2013 2.638.369 -69.57%
2014 2.452.503 -7.58%
2015 2.312.311 -6.06%
2016 3.044.109 24.04%
2017 2.860.083 -6.43%
2018 2.209.804 -29.43%
2019 2.976.526 25.76%
2020 4.099.576 27.39%
2021 4.903.662 16.4%
2022 5.688.248 13.79%
2023 7.935.680 28.32%
2023 7.510.331 -5.66%
2024 7.430.117.000 99.9%
2025 10.483.432 -70774.85%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Aethlon Medical, Inc. EBITDA
Year EBITDA Growth
1997 -1.534
1998 -3.599 57.38%
1999 -316.120 98.86%
2000 -607.129 47.93%
2001 -990.015 38.67%
2002 -1.872.357 47.12%
2003 -1.142.994 -63.81%
2004 -868.549 -31.6%
2005 -2.074.732 58.14%
2006 -1.310.530 -58.31%
2007 1.711.148 176.59%
2008 -1.746.986 197.95%
2009 971 180016.17%
2010 -2.671.978 100.04%
2011 -7.311.440 63.45%
2012 1.040.750 802.52%
2013 -3.564.870 129.19%
2014 -3.034.841 -17.46%
2015 -3.955.501 23.28%
2016 -4.346.310 8.99%
2017 -6.065.944 28.35%
2018 -4.795.458 -26.49%
2019 -5.968.322 19.65%
2020 -5.903.622 -1.1%
2021 -7.851.560 24.81%
2022 -10.297.200 23.75%
2023 -12.701.384.000 99.92%
2023 -11.657.746 -108852.31%
2024 -12.277.510 5.05%
2025 -10.139.200 -21.09%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Aethlon Medical, Inc. Gross Profit
Year Gross Profit Growth
1997 0
1998 0 0%
1999 -316.120 100%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 -1.654.701.000 100%
2012 -1.058.425.379 -56.34%
2013 1.230.004 86150.56%
2014 1.623.769 24.25%
2015 762.417 -112.98%
2016 886.572 14%
2017 392.073 -126.12%
2018 149.625 -162.04%
2019 229.625 34.84%
2020 650.187 64.68%
2021 659.104 1.35%
2022 139.948 -370.96%
2023 -4.765.704.000 100%
2023 308.945 1542673.6%
2024 -359.057 186.04%
2025 -344.240 -4.3%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Aethlon Medical, Inc. Net Profit
Year Net Profit Growth
1997 -1.534
1998 -3.599 57.38%
1999 -352.679 98.98%
2000 -1.299.382 72.86%
2001 -4.423.073 70.62%
2002 -3.995.910 -10.69%
2003 -2.461.116 -62.36%
2004 -1.518.798 -62.04%
2005 -2.096.951 27.57%
2006 -2.920.183 28.19%
2007 -6.024.545 51.53%
2008 -4.140.264 -45.51%
2009 -6.084.158 31.95%
2010 -4.573.315 -33.04%
2011 -5.711.435 19.93%
2012 -8.111.340 29.59%
2013 -4.892.040 -65.81%
2014 -13.357.232 63.38%
2015 -6.797.157 -96.51%
2016 -4.872.329 -39.51%
2017 -7.276.113 33.04%
2018 -5.679.558 -28.11%
2019 -6.194.719 8.32%
2020 -6.373.948 2.81%
2021 -7.886.709 19.18%
2022 -10.416.091 24.28%
2023 -12.137.824 14.18%
2023 -12.029.786 -0.9%
2024 -12.208.174 1.46%
2025 -10.285.760 -18.69%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Aethlon Medical, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1997 -1
1998 -2 100%
1999 -176 98.86%
2000 -373 53.08%
2001 -1.193 68.73%
2002 -781 -52.95%
2003 -332 -134.94%
2004 -139 -138.85%
2005 -112 -24.11%
2006 -112 0%
2007 -168 32.93%
2008 -90 -85.56%
2009 -106 15.09%
2010 -61 -76.67%
2011 -62 1.64%
2012 -60 -3.39%
2013 -246 75.92%
2014 -516 52.52%
2015 -182 -183.52%
2016 -99 -85.71%
2017 -141 30%
2018 -69 -102.9%
2019 -51 -35.29%
2020 -19 -183.33%
2021 -7 -200%
2022 -7 14.29%
2023 -5 -75%
2023 -6 20%
2024 -5 -25%
2025 -1 -300%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Aethlon Medical, Inc. Free Cashflow
Year Free Cashflow Growth
1997 -2.219
1998 -1.850 -19.95%
1999 -122.750 98.49%
2000 -692.403 82.27%
2001 -807.145 14.22%
2002 -1.007.431 19.88%
2003 -515.701 -95.35%
2004 -546.838 5.69%
2005 -1.589.436 65.6%
2006 -1.599.932 0.66%
2007 -1.736.714 7.88%
2008 -2.115.815 17.92%
2009 -1.778.795 -18.95%
2010 -1.994.585 10.82%
2011 -1.970.874 -1.2%
2012 -1.843.090 -6.93%
2013 -2.098.857 12.19%
2014 -2.235.027 6.09%
2015 -5.049.414 55.74%
2016 -4.338.614 -16.38%
2017 -3.522.333 -23.17%
2018 -3.935.503 10.5%
2019 -4.293.433 8.34%
2020 -5.349.273 19.74%
2021 -6.824.821 21.62%
2022 -10.116.350 32.54%
2023 -2.710.916 -273.17%
2023 -11.448.237 76.32%
2024 -10.380.677 -10.28%
2025 -1.747.537 -494.02%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Aethlon Medical, Inc. Operating Cashflow
Year Operating Cashflow Growth
1997 -2.219
1998 -1.850 -19.95%
1999 -122.750 98.49%
2000 -678.927 81.92%
2001 -800.667 15.2%
2002 -1.007.431 20.52%
2003 -514.503 -95.81%
2004 -542.056 5.08%
2005 -1.559.366 65.24%
2006 -1.584.281 1.57%
2007 -1.718.904 7.83%
2008 -2.104.272 18.31%
2009 -1.777.388 -18.39%
2010 -1.977.517 10.12%
2011 -1.968.333 -0.47%
2012 -1.841.355 -6.9%
2013 -2.098.857 12.27%
2014 -2.138.971 1.88%
2015 -5.049.414 57.64%
2016 -4.329.307 -16.63%
2017 -3.505.900 -23.49%
2018 -3.910.680 10.35%
2019 -4.293.433 8.91%
2020 -5.197.608 17.4%
2021 -6.764.940 23.17%
2022 -9.767.157 30.74%
2023 -2.704.146 -261.19%
2023 -10.505.128 74.26%
2024 -10.129.810 -3.71%
2025 -1.747.537 -479.66%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Aethlon Medical, Inc. Capital Expenditure
Year Capital Expenditure Growth
1997 0
1998 0 0%
1999 0 0%
2000 13.476 100%
2001 6.478 -108.03%
2002 0 0%
2003 1.198 100%
2004 4.782 74.95%
2005 30.070 84.1%
2006 15.651 -92.13%
2007 17.810 12.12%
2008 11.543 -54.29%
2009 1.407 -720.4%
2010 17.068 91.76%
2011 2.541 -571.7%
2012 1.735 -46.46%
2013 0 0%
2014 96.056 100%
2015 0 0%
2016 9.307 100%
2017 16.433 43.36%
2018 24.823 33.8%
2019 0 0%
2020 151.665 100%
2021 59.881 -153.28%
2022 349.193 82.85%
2023 6.770 -5057.95%
2023 943.109 99.28%
2024 250.867 -275.94%
2025 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Aethlon Medical, Inc. Equity
Year Equity Growth
1997 2.374
1998 -1.225 293.8%
1999 -704.496 99.83%
2000 -713.052 1.2%
2001 -2.465.991 71.08%
2002 -2.197.536 -12.22%
2003 -3.625.597 39.39%
2004 -3.655.177 0.81%
2005 -3.066.971 -19.18%
2006 -1.759.486 -74.31%
2007 -7.091.670 75.19%
2008 -3.322.264 -113.46%
2009 -3.949.300 15.88%
2010 -4.402.234 10.29%
2011 -5.975.698 26.33%
2012 -9.295.621 35.71%
2013 -9.144.444 -1.65%
2014 -14.730.166 37.92%
2015 651.383 2361.37%
2016 1.502.366 56.64%
2017 595.412 -152.32%
2018 6.032.794 90.13%
2019 2.299.078 -162.4%
2020 9.277.426 75.22%
2021 9.293.690 0.18%
2022 16.991.400 45.3%
2023 10.319.344 -64.66%
2023 15.064.210 31.5%
2024 5.766.332 -161.24%
2025 8.712.616 33.82%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Aethlon Medical, Inc. Assets
Year Assets Growth
1997 2.724
1998 754 -261.27%
1999 82.073 99.08%
2000 1.320.008 93.78%
2001 1.283.940 -2.81%
2002 973.538 -31.88%
2003 398.520 -144.29%
2004 281.661 -41.49%
2005 300.352 6.22%
2006 1.029.776 70.83%
2007 613.358 -67.89%
2008 488.105 -25.66%
2009 197.388 -147.28%
2010 646.001 69.44%
2011 567.219 -13.89%
2012 838.694 32.37%
2013 496.694 -68.86%
2014 1.695.102 70.7%
2015 1.380.588 -22.78%
2016 2.556.757 46%
2017 1.726.368 -48.1%
2018 7.351.904 76.52%
2019 4.122.964 -78.32%
2020 10.387.686 60.31%
2021 10.668.916 2.64%
2022 19.417.954 45.06%
2023 12.828.329 -51.37%
2023 17.508.940 26.73%
2024 8.245.982 -112.33%
2025 11.415.417 27.76%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Aethlon Medical, Inc. Liabilities
Year Liabilities Growth
1997 350
1998 1.979 82.31%
1999 786.569 99.75%
2000 2.033.060 61.31%
2001 3.749.931 45.78%
2002 3.171.074 -18.25%
2003 4.024.117 21.2%
2004 3.936.838 -2.22%
2005 3.367.323 -16.91%
2006 2.789.262 -20.72%
2007 7.705.028 63.8%
2008 3.810.369 -102.21%
2009 4.146.688 8.11%
2010 5.048.235 17.86%
2011 6.542.917 22.84%
2012 10.134.315 35.44%
2013 9.641.138 -5.12%
2014 16.425.268 41.3%
2015 729.205 -2152.49%
2016 1.054.391 30.84%
2017 1.130.956 6.77%
2018 1.319.110 14.26%
2019 1.823.886 27.68%
2020 1.110.260 -64.28%
2021 1.375.226 19.27%
2022 2.426.554 43.33%
2023 2.508.985 3.29%
2023 2.444.730 -2.63%
2024 2.479.650 1.41%
2025 2.702.800 8.26%

Aethlon Medical, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-1.54
Price to Earning Ratio
-0.26x
Price To Sales Ratio
0x
POCF Ratio
-0.32
PFCF Ratio
-0.59
Price to Book Ratio
0.34
EV to Sales
0
EV Over EBITDA
0.25
EV to Operating CashFlow
0.28
EV to FreeCashFlow
0.28
Earnings Yield
-3.88
FreeCashFlow Yield
-1.7
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
6.37
Graham NetNet
0.85

Income Statement Metrics

Net Income per Share
-1.54
Income Quality
0.82
ROE
-1.42
Return On Assets
-318.22
Return On Capital Employed
-1.64
Net Income per EBT
1
EBT Per Ebit
263.04
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.26
Free CashFlow per Share
-1.26
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.06
Return on Invested Capital
-1.15
Return on Tangible Assets
-1.01
Days Sales Outstanding
0
Days Payables Outstanding
1098.49
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.33
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
1,22
Book Value per Share
1,17
Tangible Book Value per Share
1.17
Shareholders Equity per Share
1.17
Interest Debt per Share
0.12
Debt to Equity
0.1
Debt to Assets
0.08
Net Debt to EBITDA
0.77
Current Ratio
4.49
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
9165658
Working Capital
0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Aethlon Medical, Inc. Dividends
Year Dividends Growth

Aethlon Medical, Inc. Profile

About Aethlon Medical, Inc.

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

CEO
Mr. James B. Frakes M.B.A.
Employee
14
Address
11555 Sorrento Valley Road
San Diego, 92121

Aethlon Medical, Inc. Executives & BODs

Aethlon Medical, Inc. Executives & BODs
# Name Age
1 Dr. Steven P. LaRosa M.D.
Chief Medical Officer
70
2 Mr. Guy F. Cipriani BS (Eng.), MBA
Senior Vice President & Chief Operating Officer
70
3 Mr. James B. Frakes M.B.A.
Chief Executive Officer, Chief Financial Officer, Secretary & Director
70

Aethlon Medical, Inc. Competitors